on major coronary events in hypercholesterolaemic patients (JELIS): a Shirato K; Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded. Significant reduction in residual risk in patients treated with statins. Results from the JELIS (Japan EPA Lipid Intervention Study) trial. EPA may have beneficial.

Author: Vot Kigami
Country: Paraguay
Language: English (Spanish)
Genre: Business
Published (Last): 2 October 2006
Pages: 498
PDF File Size: 20.63 Mb
ePub File Size: 9.22 Mb
ISBN: 356-2-72830-360-2
Downloads: 94605
Price: Free* [*Free Regsitration Required]
Uploader: Taur

The primary endpoint was any major coronary event, including sudden cardiac death, fatal and non-fatal myocardial infarction, and other non-fatal events including unstable angina pectoris, angioplasty, stenting, or coronary artery bypass grafting. Curves were visually truncated at 5. These observations suggest that at least some of the impact of VASCEPA on the reduction in ischemic events may be explained by metabolic effects other than triglyceride lowering.

This information on inflammatory markers cannot be used in isolation. Overall adverse stuey rates were similar across treatment groups.

In patients with severe hypertriglyceridemia, the effect of VASCEPA on cardiovascular mortality or morbidity or on the risk of pancreatitis has not been determined. Patients enrolled were treated with statin therapy at baseline with most Jlis supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Watch the national commercial.

Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: We aimed to test the hypothesis that long-term use of eicosapentaenoic acid EPA is effective for prevention of major coronary events in hypercholesterolaemic patients in Japan who consume a large amount of fish. We encourage you to check that for yourself.


This offer is not valid for those patients under 18 years of age or patients whose plans do not permit use of a copay card. P values from Wilcoxon rank sum test. By browsing our website, you agree to our use of cookies. Mineral oil placebo consideration and analysis.

N Engl J Med. The median change in LDL-C was 3.

VASCEPA® (icosapent ethyl) | REDUCE-IT™ Results Announced

Amarin, through its dedicated jeliw of professionals, constantly seeks to improve patient care through its actions and products while also striving to continuously improve along the way. The median age at baseline was 64 years range: The rate of treatment-emergent serious adverse events for bleeding was 2.

This site uses cookies to give you the best possible experience. Void where prohibited by law, taxed, or restricted.

No head-to-head cardiovascular outcomes study of EPA vs a mixture of omega-3 acids has been conducted.

About Amarin

Analysis was by intention-to-treat. Epidemiological and clinical evidence suggests that an increased intake of long-chain n-3 fatty acids protects against mortality from coronary artery disease. The study was registered at ClinicalTrials.

GISSI-P did not suggest an effect on the incidence of nonfatal cardiovascular events and the effects of omega-3 fatty acids on lipids, including serum TGs, were negligible. While the DMC noted variation in LDL-C measurements in both arms and that a small physiological effect of mineral oil might be possible, the DMC concluded that it was not possible to determine if the LDL-C increase in the placebo arm was a natural increase over time or due to the mineral oil, wtudy found no apparent effect jdlis outcomes and found that this small change was unlikely to explain the observed benefit of VASCEPA over placebo.

Adapted from Yokoyama et al, Figure 3: Yes No By clicking yes, you are certifying you are also a US resident. Most patients at baseline were taking at least one other cardiovascular medication including anti-platelet agents Only subjects with non-missing baseline and week 12 values are included.


Offer good through December 31, Am J Cardiovasc Drugs.

Further detailed data assessment by Amarin and regulatory authorities will continue and take several months to complete and record The final evaluation of the totality of the efficacy and safety data from REDUCE-IT may include some or all of the following, as well as other considerations: On stable background lipid-lowering therapy, the median [Q1, Q3] fasting TG was Unstable angina and non-fatal coronary events were also significantly reduced in the EPA group.

EPA is a promising treatment for prevention of major coronary events, and especially non-fatal coronary events, in Japanese hypercholesterolaemic patients. While overall adverse event rates were similar across treatment groups Numerically more serious adverse events related to bleeding; overall rates were low 2.

The primary, secondary, and stjdy adjudicated endpoint analyses were validated by the data monitoring committee independent statistician. Adverse events and serious adverse events leading to study drug discontinuation were similar to placebo.

At mean follow-up of 4.

CI denotes confidence interval. GISSI-P is an open-label outcomes trial 1 g omega-3 fatty acid mixturejeils in Italy, that supported the hypothesis that omega-3 fatty acids likely exert their cardioprotective effects through nonlipid-mediated mechanisms. United States Food and Drug Administration et al.